JS007

DRUG3 trials

Sponsors

Shanghai Junshi Bioscience Co., Ltd., Fudan University

Conditions

Hepatocellular CarcinomaPancreatic CancerPatients With Advanced Solid Tumors

Phase 1

Clinical Study of JS007 in Patients With Advanced Solid Tumors

Shanghai Junshi Bioscience Co., Ltd.Patients With Advanced Solid Tumors

Start: 2021-11-17End: 2022-09-20Target: 42Updated: 2021-11-23

Newly Emerging Immunotherapy for Pancreatic Cancer Treatment

Not yet recruitingNCT06370754

Fudan UniversityPancreatic Cancer

Start: 2024-04-30End: 2027-04-30Target: 117Updated: 2024-04-17

Phase 2

JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma

RecruitingNCT06954467

Shanghai Junshi Bioscience Co., Ltd.Hepatocellular Carcinoma

Start: 2025-05-29End: 2028-06-30Target: 72Updated: 2025-07-02

Related Papers

Preclinical investigations and a first-in-human phase 1a trial of JS007, a novel anti-CTLA-4 antibody, in patients with advanced solid tumors.

2024-10-011 citations